• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Vadadustat noninferior to darbepoetin for treating anemia in dialysis patients

byNhat Hung (Benjamin) LamandHarsh Shah
May 4, 2021
in Cardiology, Chronic Disease, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Vadadustat was shown to be non-inferior to darbepoetin alfa in cardiovascular safety for patients with anemia and dialysis-dependent chronic kidney disease (DD-CKD).

2. Vadadustat was shown to present comparable efficacy in normalizing hemoglobin concentration compared to darbepoetin alfa in the patient population.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Chronic kidney disease is commonly associated with anemia, due to erythropoietin decline, resulting in reduced quality of life and increase red-cell transfusions. Darbepoetin alfa mimics erythropoietin activity and is the standard of care for treating anemia in this patient population. However, darbepoetin alfa increases the risk of cardiovascular events and death. As such, this study examined the hematologic efficacy and cardiovascular safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with anemia and DD-CKDs compared to darbepoetin alfa. The study determined vadadustat exhibited comparable time to the first occurrence of a major adverse cardiovascular event (MACE) and hospitalization rate compared to darbepoetin alfa. Furthermore, vadadustat showed similar improvements in hemoglobin compared to darbepoetin alfa. The study was limited by open-label design preventing assessment of patient-reported symptoms. Nonetheless, the study’s results are significant, as this study demonstrated the safety and efficacy of vadadustat to manage anemia in DD-CKD patients.

Clicker to read the study in NEJM

Relevant Reading: Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: A Phase 3, multicenter, randomized, double-blind study

RELATED REPORTS

#VisualAbstract: Empagliflozin Has Cardiorenal Benefits for Chronic Kindey Disease

Prevalence of common chronic conditions in Medicare Advantage and traditional Medicare beneficiaries

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

In-Depth [randomized controlled trial]: This study pooled results from two randomized controlled trials, enrolling 369 patients with incident DD-CKD and 3554 with prevalent DD-CKD. Adult patients were included if they were undergoing dialysis, had at least 100ng/mL serum ferritin, and at least 20% transferrin saturation. Patients were excluded if they had anemia due to causes other than CKD, uncontrolled hypertension, or a recent cardiovascular event. Patients were randomized in a 1:1 ratio to receive either vadadustat or darbepoetin alfa, respectively. Dosage was adjusted to achieve hemoglobin targets (according to regional guidelines). The primary safety endpoint was time to the first occurrence of a MACE, which was defined as a composite endpoint of death from any cause, nonfatal myocardial infarction, or a nonfatal stroke. The primary efficacy endpoint was the mean change in hemoglobin level from baseline during the primary (weeks 24-36) and secondary (weeks 40-52) evaluation periods. The cumulative probabilities of a first MACE were comparable between vadadustat (18.2%) and darbepoetin alfa (19.4%) (hazard ratio, 0.96; 95% confidence interval [CI], 0.83 to 1.11). In the incident DD-CKD trial, the mean between-group differences in the change in hemoglobin concentration were -0.31 g/dL (standard deviation [SD], 0.11; 95% CI, -0.53 to -0.10) at primary evaluation and -0.07 g/dL (SD, 0.13; 95% CI, -0.34 to 0.19) at secondary evaluation. In the prevalent DD-CKD trial, the mean between-group differences in the change in hemoglobin concentration were -0.17g/dL (SD, 0.03; 95% CI, -0.23 to -0.10) at primary evaluation and -0.18g/dL (SD, 0.04; 95% CI, -0.25 to -0.12) at secondary evaluation. Overall, vadadustat was non-inferior to darbepoetin alfa in safety and efficacy profiles for the management of anemia in DD-CKD.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular eventschronic kidney disease (CKD)Darbepoetin alfadialysisVadadustat
Previous Post

Childhood fat mass more strongly associated with adult-onset type 2 diabetes risk than childhood weight

Next Post

Younger age of onset of type 2 diabetes linked to higher risk of dementia

RelatedReports

#VisualAbstract: Empagliflozin Has Cardiorenal Benefits for Chronic Kindey Disease
StudyGraphics

#VisualAbstract: Empagliflozin Has Cardiorenal Benefits for Chronic Kindey Disease

March 6, 2025
Chronic Disease

Prevalence of common chronic conditions in Medicare Advantage and traditional Medicare beneficiaries

February 25, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Chronic Disease

Denosumab may increase risk of major adverse cardiovascular events but reduce fracture risk in patients receiving dialysis

January 13, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Nephrology

Denosumab increases risk of severe hypocalcemia in women with osteoporosis and chronic kidney disease

November 18, 2024
Next Post
Food environment associated with gestational diabetes

Younger age of onset of type 2 diabetes linked to higher risk of dementia

Intensive rehabilitation not superior to traditional therapy for arm function after stroke

Vagus nerve stimulation therapy improves motor function after stroke

#VisualAbstract: ChAdOx1 nCov-19 AstraZeneca COVID-19 vaccine not effective against B.1.351 variant

#VisualAbstract: Sacituzumab govitecan increased survival in metastatic triple-negative breast cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Tirzepatide-associated improvements in cardiometabolic risk factors linked to degree of weight loss
  • Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
  • 2 Minute Medicine Rewind June 23, 2025
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.